Modelling shows dabigatran benefit

UK experts in pharmacology and statistics, funded by the Medical Research Council, compared costs and quality-adjusted life years (QALYs) gained among 50,000 simulated patients, at moderate to high risk of stroke,
treated with 110 mg or 150 mg of dabigatran twice daily compared to warfarin.